Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Health Aff (Millwood) ; 25(5): 1231-9, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16966718

RESUMO

Payers point to the lack of unbiased evidence for making coverage decisions for new and often costly technologies. This paper provides a case study of a new approach to developing information to meet the needs of a payer: Medicare's coverage with evidence development (CED) policy. Medicare's decision to condition coverage of cancer therapies on clinical trial participation is an early application of CED and signals Medicare's interest in developing evidence on new technologies for beneficiaries. This paper reviews the rationale and challenges Medicare faces in applying its CED policy and discusses the implications of payers' using and generating evidence.


Assuntos
Antineoplásicos/economia , Neoplasias Colorretais/tratamento farmacológico , Seguro de Serviços Farmacêuticos , Medicare , Ensaios Clínicos como Assunto , Neoplasias Colorretais/economia , Medicina Baseada em Evidências , Humanos , Estudos de Casos Organizacionais , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA